TY - JOUR
T1 - Cost savings with a novel algorithm for early detection of systemic sclerosis-related pulmonary arterial hypertension
T2 - alternative scenario analyses
AU - Australian Scleroderma Interest Group (ASIG)
AU - Quinlivan, Alannah
AU - Proudman, Susanna
AU - Sahhar, Joanne
AU - Stevens, Wendy
AU - Nikpour, Mandana
AU - Major, Gabor
AU - Ngian, Gene Siew
AU - Roddy, Janet
AU - Strickland, Gemma
AU - Walker, Jennifer
AU - Youseff, Peter
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Pulmonary arterial hypertension is an important cause of death and disability in patients with systemic sclerosis (SSc). Yearly screening of all SSc patients with transthoracic echocardiography (TTE) is recommended in international guidelines and currently utilised by the Australian Scleroderma Interest Group (ASIGSTANDARD). Owing to the limitations of TTE, the ASIG developed a new screening algorithm (ASIGPROPOSED) utilising a serum biomarker, NT-proBNP, in place of TTE, which has been shown to be equally accurate as the current algorithm. The aim of this study was to compare the cost of these two algorithms using different scenarios. The new algorithm resulted in significant yearly cost savings of between AU$42 913.35 and AU$84 570 in screening and diagnosis of an Australian cohort which, if extrapolated to the Australian population, would result in a yearly cost saving of between AU$367 066 and AU$725 564. There was no scenario in which the proposed algorithm did not result in a cost saving.
AB - Pulmonary arterial hypertension is an important cause of death and disability in patients with systemic sclerosis (SSc). Yearly screening of all SSc patients with transthoracic echocardiography (TTE) is recommended in international guidelines and currently utilised by the Australian Scleroderma Interest Group (ASIGSTANDARD). Owing to the limitations of TTE, the ASIG developed a new screening algorithm (ASIGPROPOSED) utilising a serum biomarker, NT-proBNP, in place of TTE, which has been shown to be equally accurate as the current algorithm. The aim of this study was to compare the cost of these two algorithms using different scenarios. The new algorithm resulted in significant yearly cost savings of between AU$42 913.35 and AU$84 570 in screening and diagnosis of an Australian cohort which, if extrapolated to the Australian population, would result in a yearly cost saving of between AU$367 066 and AU$725 564. There was no scenario in which the proposed algorithm did not result in a cost saving.
KW - Australian Scleroderma Interest Group
KW - NT-proBNP
KW - pulmonary arterial hypertension
KW - screening
KW - systemic sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85067172045&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/nhmrc/1126370
U2 - 10.1111/imj.14316
DO - 10.1111/imj.14316
M3 - Article
C2 - 31185523
AN - SCOPUS:85067172045
VL - 49
SP - 781
EP - 785
JO - Internal Medicine Journal
JF - Internal Medicine Journal
SN - 0004-8291
IS - 6
ER -